Investors Buy Shares of Becton, Dickinson and Company (BDX) on Weakness

Traders purchased shares of Becton, Dickinson and Company (NYSE:BDX) on weakness during trading hours on Wednesday. $93.42 million flowed into the stock on the tick-up and $49.64 million flowed out of the stock on the tick-down, for a money net flow of $43.78 million into the stock. Of all equities tracked, Becton, Dickinson and had the 20th highest net in-flow for the day. Becton, Dickinson and traded down ($2.60) for the day and closed at $224.23

BDX has been the topic of a number of research reports. BidaskClub cut Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Stifel Nicolaus reaffirmed a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $213.00 price target on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Cowen Inc reaffirmed a “buy” rating and issued a $230.00 price target on shares of Becton, Dickinson and in a research note on Monday, August 14th. Finally, Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price target on the stock in a research note on Tuesday, October 31st. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Becton, Dickinson and currently has an average rating of “Buy” and an average target price of $217.08.

The company has a quick ratio of 5.01, a current ratio of 5.56 and a debt-to-equity ratio of 1.48. The stock has a market capitalization of $51,119.57, a P/E ratio of 23.63, a P/E/G ratio of 1.76 and a beta of 1.04.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, topping the Zacks’ consensus estimate of $2.37 by $0.03. The business had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The business’s quarterly revenue was down 2.0% on a year-over-year basis. During the same period in the previous year, the firm earned $2.12 EPS. equities research analysts forecast that Becton, Dickinson and Company will post 10.63 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be given a $0.75 dividend. This is a positive change from Becton, Dickinson and’s previous quarterly dividend of $0.73. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.34%. The ex-dividend date is Thursday, December 7th. Becton, Dickinson and’s dividend payout ratio (DPR) is currently 62.80%.

In other news, insider Stephen Sichak sold 11,787 shares of Becton, Dickinson and stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $200.46, for a total value of $2,362,822.02. Following the sale, the insider now directly owns 14,038 shares in the company, valued at approximately $2,814,057.48. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the sale, the insider now owns 95,781 shares in the company, valued at $19,517,294.37. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by company insiders.

Several hedge funds have recently modified their holdings of the company. Steward Partners Investment Advisory LLC bought a new stake in shares of Becton, Dickinson and in the 3rd quarter worth approximately $1,365,000. Garde Capital Inc. bought a new stake in shares of Becton, Dickinson and in the 3rd quarter worth approximately $1,019,000. Smith Shellnut Wilson LLC ADV grew its position in shares of Becton, Dickinson and by 16.7% in the 3rd quarter. Smith Shellnut Wilson LLC ADV now owns 2,566 shares of the medical instruments supplier’s stock worth $503,000 after buying an additional 368 shares during the last quarter. Hahn Capital Management LLC grew its position in shares of Becton, Dickinson and by 1.0% in the 3rd quarter. Hahn Capital Management LLC now owns 217,342 shares of the medical instruments supplier’s stock worth $42,588,000 after buying an additional 2,055 shares during the last quarter. Finally, Americafirst Capital Management LLC bought a new stake in shares of Becton, Dickinson and in the 3rd quarter worth approximately $690,000. Hedge funds and other institutional investors own 87.91% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://sportsperspectives.com/2017/11/24/investors-buy-shares-of-becton-dickinson-and-company-bdx-on-weakness.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply